Navigation Links
Nventa Appoints Gordon H. Busenbark to Board of Directors
Date:5/28/2008

- Busenbark Provides Additional Global Corporate Finance, Management and

Manufacturing Experience -

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of Gordon H. Busenbark to the company's board of directors. Mr. Busenbark currently serves as the chief financial officer of Xytis Pharmaceuticals, a privately held development-stage specialty pharmaceuticals company focused on diseases of the central nervous system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"With his extensive experience in the pharmaceutical, biotech and vaccine industries, Gordon is a valuable addition to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His 28 years of industry experience include overseeing billion dollar businesses in both the U.S. and Europe. We believe this key global experience, coupled with his proven track record in corporate finance and manufacturing, will serve Nventa well as we continue to advance our lead product candidate through development and toward commercialization."

Prior to joining Xytis in 2007, Mr. Busenbark was the chief financial officer of Encysive Pharmaceuticals, a publicly traded specialty pharmaceuticals company focused on vascular disease. In this role, he was responsible for securing external financing, all aspects of Security and Exchange Commission (SEC) reporting, Sarbanes-Oxley compliance, budgeting, forecasting, strategic planning and investor relations activities. From 1981 through 2004, Mr. Busenbark held various leadership positions with Baxter Healthcare Corporation, including president of Baxter BioScience's plasma therapeutics business in Vienna, Austria. Mr. Busenbark began his career as a senior financial analyst at Burroughs Corporation. He received a bachelo
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/25/2014)... report “Service Quality Management and Telco Customer Experience Management ... Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines and segments ... revenues. , Browse 152 market data tables, 19 ... “Service Quality Management (SQM) and Telco Customer Experience Management ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Precision Therapeutics, Inc. will present pancreatic cancer data based ... Society of Clinical Oncology (ASCO) GI Symposium, January 20-22 in ... by the ASCO GI are titled, ... Cancer and Pattern of In Vitro Chemotherapy Response ...
... at Northwestern University have placed nanocrystals of rock salt ... electricity from heat-generating items such as vehicle exhaust systems, ... than scientists have seen in the past. The ... is expected to enable 14 percent of heat waste ...
... CITY, N.J., Jan. 18, 2011 Intrasphere Technologies ... and solutions firm that provides services to Life ... a Gold level member of Oracle PartnerNetwork (OPN) ... Safety Suite. As a result of this accomplishment, ...
Cached Biology Technology:Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx® in Cancer Treatment Options 2Breakthrough in converting heat waste to electricity 2Intrasphere Technologies Achieves Oracle PartnerNetwork Specialization for Oracle Argus Safety Suite 2Intrasphere Technologies Achieves Oracle PartnerNetwork Specialization for Oracle Argus Safety Suite 3
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button Synaptics ... http://photos.prnewswire.com/prnh/20130307/600769 ... iPhone 5S, Samsung introduces for the first time a ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Hopkins have discovered that a tiny piece of genetic code ... and it gets there under its own internal code. , ... that directs its movement, will be published Jan. 5 in ... development, latch on to and gum up larger strands of ...
... risk factor for Alzheimer's disease puts out the welcome mat for ... more active in the brain compared to other forms of the ... Aging, add some scientific heft to the idea, long suspected by ... Alzheimer's disease. , The work links a form of the ApoE ...
... percent of men treated with a combination of radiation ... cancer are cured of their disease 15 years following ... the International Journal of Radiation Oncology*Biology*Physics, the official journal ... physicians at the Seattle Prostate Institute. Doctors wanted to ...
Cached Biology News:Renegade RNA -- Clues to cancer and normal growth 2Cold sore virus might play role in Alzheimer's disease 2Cold sore virus might play role in Alzheimer's disease 3Cold sore virus might play role in Alzheimer's disease 4
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Biology Products: